RxDoctor Payments Data

Abdallah Karam, MD

Internal Medicine · Arlington Heights, ILNPI 1144257395

Payments from drug & device makers

$623in general payments, 2019–2025

Across 36 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$147
  • Amgen$72
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
  • Sanofi-aventis U.S. LLC$58
  • Gilead$48
  • Takeda Pharmaceuticals U.S.A., Inc.$35
  • plus $194 from 9 others

What the payments were for

  • Speaking & faculty fees$457%
  • Food & beverage$57893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$623 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$126,912
Medicare patients
274
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$78,197
Soliqua 100-33Insulin Glargine/Lixisenatide37$70,286
JulucaDolutegravir/Rilpivirine11$45,037
XareltoRivaroxaban27$42,960
MounjaroTirzepatide32$41,672
JardianceEmpagliflozin22$30,871
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$29,690
OzempicSemaglutide20$27,633
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,716
SynjardyEmpagliflozin/Metformin Hcl23$18,900
FarxigaDapagliflozin Propanediol20$18,666
MyrbetriqMirabegron20$18,263
Synjardy XrEmpagliflozin/Metformin Hcl11$11,027
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,460
VascepaIcosapent Ethyl12$4,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$32$79,65867 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$58$70,28637 claims
Johnson & JohnsonXarelto$20$42,96027 claims
Novo NordiskOzempic$147$27,63320 claims
AstraZenecaFarxiga$30$18,66620 claims
Astellas Pharma US IncMyrbetriq$20$18,26320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →